CKM syndrome
Conditions
Interventions
Sponsors
Zhongshan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. From July 22, 2025, to May 31, 2026, first-time prescriptions of GLP-1 receptor agonists (dulaglutide, exenatide, liraglutide, semaglutide) and/or SGLT-2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin). 2. Patients aged 18-75. 3. Patients meet the definition of cardiorenal metabolic syndrome, with distinctions made based on the disease stage of each patient.
Exclusion criteria
Exclusion criteria: 1. Patients previously diagnosed with type 1 diabetes; 2. Patients with contraindications to the study drug, such as end-stage kidney disease and multiple endocrine neoplasia; 3. Patients lacking important clinical data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Major cardiovascular events (including cardiovascular death, non-fatal heart attack, and non-fatal stroke);Major kidney events (including eGFR drop >=50%, end-stage renal disease (ESRD), kidney-related death); | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse drug reactions;Hospitalization of heart failure;Fasting glucose;All cause death;Change rate of eGFR;Change of UACR; | — |
Countries
China
Contacts
Public ContactQin Yan
Zhongshan Hospital, Fudan University
Outcome results
None listed